___

• 1. Sridhar R, Ramya SS, Sowjanya S. Rheumatoid arthritis - a review. World J Pharm Pharm Sci 2016;5(10):1283–302. 2. Xu B, Lin J. Characteristics and risk factors of rheumatoid arthritis in the United States: An NHANES analysis. PeerJ 2017;24(5). 3. Mcinnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011;365(23):2205–19. 4. Cooles FA, Isaacs JD. Pathophysiology of rheumatoid arthritis. Curr Opin Rheumatol 2011;23(3):233–40. 5. Miura Y, Ota S, Peterlin M et al. Subpopulation of synovial fibroblasts leads to osteochondrogenesis in a mouse model of chronic inflammatory rheumatoid arthritis. JBMR Plus 2018;3(6):1–10. 6. Mellado M, Martinz-Munoz L, Cascio G et al. T cell migration in rheumatoid arthritis. Front Immunol 2015;6:384. 7. Bustamante MF, Garcia-Carbonell R, Whisenant KD et al. Fibroblast-like synoviocyte metabolism in the pathogenesis of rheumatoid arthritis. Arthritis Res Ther 2017;19(110):1–12. 8. Xu L, Zhang Y, Wang Q et al. Bi-specific antibodies with high antigen-binding affinity identified by flow cytometry. Int Immunopharmacol 2015;24(2):463–73. 9. Byrne H, Conroy PJ, Whisstock JC et al. A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications. Trends Biotechnol 2013;31(11):621-32. 10. Taylor P, Kontermann RE. Dual targeting strategies with bispecific antibodies. mAbs 2012;4(2):182-97. 11. Spiess C, Zhai Q, Carter PJ. Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol Immunol 2015;67(2):95–106. 12. Chon JH, Zarbis-Papastoitsis G. Advances in the production and downstream processing of antibodies. N Biotechnol 2011;28(5):458– 63. 13. Klein C, Schaefer W, Regula JT et al. Engineering therapeutic bispecific antibodies using CrossMab technology. Methods 2019;154:21–31. 14. Michal P, Timo R, Wagne IL et al. FcRn: the architect behind the immune and non-immune functions of IgG and albumin. J Immunol 2015;194(10):4595–603. 15. Levin D, Golding B, Strome SE et al. Fc fusion as a platform technology: potential for modulating immunogenicity. Trends Biotechnol 2015;33(1):27–34. 16. Sedykh SE, Prinz VV, Buneva VN et al. Bispecific antibodies: design, therapy, perspectives. Drug Des Devel Ther 2018;12:195–208. 17. Xu T, Ying T, Wang L et al. A native-like bispecific antibody suppresses the inflammatory cytokine response by simultaneously neutralizing tumor necrosis factor-alpha and interleukin-17A. Oncotarget 2017;8(47):81860–72. 18. Noack M, Beringer A, Miossec P. Additive or synergistic interactions between IL-17A or IL-17F and TNF or IL-1β depend on the cell type. Front Immunol 2019;10:1–12. 19. Yoshitomi H. Regulation of immune responses and chronic inflammation by fibroblast-like synoviocytes. Front Immunol 2019;10:1–8. 20. Liu Z, Song L, Wang Y et al. A novel fusion protein attenuates collagen – induced arthritis by targeting interleukin 17A and tumor necrosis factor α. Int J Pharm 2018;547(1– 2):72–82. 21. Fischer J, Hueber A, Wilson S et al. Combined inhibition of TNFα and IL-17 as therapeutic opportunity for treatment in rheumatoid arthritis: development and characterization of a novel bispecific antibody. Arthritis Rheumatol 2015;67(1):51–62. 22. Alzabin S, Abraham SM, Taher TE et al. Incomplete response of inflammatory arthritis to TNF-α blockade is associated with the Th17 pathway. Ann Rheum Dis 2012;71(10):1741–8.